- Report
- July 2025
- 150 Pages
Global
From €3380EUR$3,850USD£2,940GBP
€4258EUR$4,850USD£3,704GBP
- Report
- August 2025
- 197 Pages
Global
From €3112EUR$3,545USD£2,707GBP
€3458EUR$3,939USD£3,008GBP
- Report
- August 2025
- 193 Pages
Global
From €3112EUR$3,545USD£2,707GBP
€3458EUR$3,939USD£3,008GBP
- Report
- September 2025
- 250 Pages
Global
From €3942EUR$4,490USD£3,429GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2634EUR$3,000USD£2,291GBP
- Report
- June 2025
- 150 Pages
Global
From €2370EUR$2,699USD£2,061GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €19315EUR$22,000USD£16,800GBP
Exelon is a brand of drugs used to treat Alzheimer's Disease. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a certain chemical in the brain that helps to reduce the symptoms of Alzheimer's. Exelon is available in both oral and patch forms, and is prescribed to treat mild to moderate Alzheimer's Disease. It is also used to treat dementia associated with Parkinson's Disease.
Exelon is one of several drugs used to treat Alzheimer's Disease, and is one of the most commonly prescribed. Other drugs used to treat Alzheimer's Disease include Aricept, Namenda, and Razadyne.
The Exelon market is highly competitive, with several major pharmaceutical companies competing for market share. Companies in the market include Novartis, Pfizer, Eisai, and Lundbeck. Show Less Read more
